Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.74 USD | +0.17% | -1.86% | -17.60% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.60% | 11.62B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+53.11% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-13.96% | 11.31B | |
-0.22% | 8.31B | |
+2.09% | 7.63B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Names Thomas Tray as Chief Accounting Officer